Option chain shows key data for Mangoceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Mangoceuticals.

Mangoceuticals (NASDAQ:MGRX) Stock, Option Chain

Mangoceuticals

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

xr:d:DAE9HpS4rJc:9180,j:2728248388,t:23041414

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

COTY

MGRX

XXII

Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter

Screenshot 2024-09-25 at 8.34.28 PM

Health Care

Interview

General

Men&#39;s Telehealth Company&#39;s Plans To Change Men&#39;s Wellness

Screenshot 2024-09-04 at 5.36.44 PM

Biotech

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Prescribing The Future: How MangoRx Is Shaking Up Telemedicine With A Fresh Platform

Mangoceuticals Inc

Throughout the last three months, 5 analysts have evaluated Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $654.0, with a high estimate of $680.00 and a low estimate of $605.00. Experiencing a 1.36% decline, the current average is now lower than the previous average price target of $663.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738350029_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Thermo Fisher Scientific's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$680.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$678.00</td>
<td>$647.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$647.00</td>
<td>$670.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$605.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$660.00</td>
<td>$675.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Thermo Fisher Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Thermo Fisher Scientific compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Thermo Fisher Scientific's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Thermo Fisher Scientific's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TMO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Thermo Fisher Scientific analyst ratings.</a>
<h2>Discovering Thermo Fisher Scientific: A Closer Look</h2>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
<h3>Thermo Fisher Scientific: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Thermo Fisher Scientific's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.23% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Thermo Fisher Scientific's net margin is impressive, surpassing industry averages. With a net margin of 15.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Thermo Fisher Scientific's ROE excels beyond industry benchmarks, reaching 3.38%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Thermo Fisher Scientific's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.64% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Thermo Fisher Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.72.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Thermo Fisher Scientific's Future

Ratings for Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $178.33, a high estimate of $185.00, and a low estimate of $172.00. This current average has increased by 7.04% from the previous average price target of $166.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1738350021_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Quest Diagnostics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$182.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$182.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$185.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quest Diagnostics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Quest Diagnostics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Quest Diagnostics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Quest Diagnostics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DGX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Quest Diagnostics analyst ratings.</a>
<h2>All You Need to Know About Quest Diagnostics</h2>
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
<h3>Key Indicators: Quest Diagnostics's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Quest Diagnostics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 8.41%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Quest Diagnostics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.04% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Quest Diagnostics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.35% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Quest Diagnostics's ROA excels beyond industry benchmarks, reaching 1.5%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.02, Quest Diagnostics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 6 Analyst Ratings Have To Say About Quest Diagnostics

In the current session, the stock is trading at $121.68, after a 4.21% spike. Over the past month, SkyWest Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) stock increased by 17.30%, and in the past year, by 104.09%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1738350021_0_0.png" alt="Past Year Chart" />

<h3>SkyWest P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 14.79 in the Passenger Airlines industry, SkyWest Inc. has a higher P/E ratio of 19.99. Shareholders might be inclined to think that SkyWest Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1738350021_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

SKYW

Price Over Earnings Overview: SkyWest

In the preceding three months, 9 analysts have released ratings for EPAM Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated EPAM Sys and provided 12-month price targets. The average target is $275.44, accompanied by a high estimate of $295.00 and a low estimate of $256.00. This upward trend is apparent, with the current average reflecting a 13.2% increase from the previous average price target of $243.33.
<img src="https://www.benzinga.com/files/images/story/2025/1738350010_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive EPAM Sys is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$256.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Surinder Thind</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$288.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$295.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Sean Kennedy</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$282.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Divya Goyal</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$275.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$270.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$258.00</td>
<td>$225.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to EPAM Sys. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EPAM Sys compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of EPAM Sys's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of EPAM Sys's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EPAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on EPAM Sys analyst ratings.</a>
<h2>About EPAM Sys</h2>
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.
<h3>EPAM Sys: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: EPAM Sys's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 1.34%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: EPAM Sys's net margin is impressive, surpassing industry averages. With a net margin of 11.68%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): EPAM Sys's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.92%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.14%, the company showcases effective utilization of assets.
Debt Management: EPAM Sys's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EPAM

EPAM Sys Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

JP Morgan analyst Samik Chatterjee maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Overweight and lowers the price target from $158 to $145.

Price Target

JP Morgan Maintains Overweight on Teradyne, Lowers Price Target to $145

JP Morgan analyst Brian Ossenbeck maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Neutral and lowers the price target from $32 to $31.

SNDR

JP Morgan Maintains Neutral on Schneider National, Lowers Price Target to $31

JP Morgan analyst Sebastiano Petti maintains Rogers Communications (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RCI#TSX">RCI</a>) with a Overweight and lowers the price target from C$63 to C$57.

TSX:RCI

TSX:RCI/B

JP Morgan Maintains Overweight on Rogers Communications, Lowers Price Target to C$57

JP Morgan analyst Andrew Steinerman maintains ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) with a Neutral and lowers the price target from $67 to $65.

JP Morgan Maintains Neutral on ManpowerGroup, Lowers Price Target to $65

JP Morgan analyst Seth Seifman maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Overweight and lowers the price target from $265 to $255.

JP Morgan Maintains Overweight on L3Harris Technologies, Lowers Price Target to $255

Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) has surged 23.4% over the past month, but technical analysts remain skeptical about the coin&#8217;s <a href="https://www.benzinga.com/money/chainlink-link-price-prediction">short-term prospect</a>s. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>)</td>
<td>&nbsp;$25.48</td>
<td>$16.3 billion</td>
<td>+2.7%&nbsp;</td>
<td>&nbsp;-2.4%</td>
</tr>
<tr>
<td>Avalanche (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/avax/usd">AVAX</a>)</td>
<td>&nbsp;$35.54</td>
<td>$14.6 billion</td>
<td>+3.2%&nbsp;</td>
<td>&nbsp;-2.9%</td>
</tr>
<tr>
<td>Stellar (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xlm/usd">XLM</a>)</td>
<td>&nbsp;$0.4188</td>
<td>$12.8 billion</td>
<td>-3.7%&nbsp;</td>
<td>-4.9%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto analyst Michael van de Poppe believes Chainlink will be crucial for banks integrating DeFi in the coming years. 
He expects significant expansion over the next six months, citing a higher low and an ongoing uptrend.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Banks can do custody in the U.S. Banks are very likely going to do <a href="https://twitter.com/hashtag/DeFi?src=hash&amp;ref_src=twsrc%5Etfw">#DeFi</a> in the coming years. What do they require?<a href="https://twitter.com/search?q=%24LINK&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$LINK</a> for data transmission / oracle. I think we&#39;ll have a significant expansion in the coming 6 months as, technically, a HL is made and trend is upward. <a href="https://t.co/Gt37PcEayM">pic.twitter.com/Gt37PcEayM</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1885309557649396112?ref_src=twsrc%5Etfw">January 31, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, technical analyst Ali Martinez noted that LINK is consolidating within a range, advising traders to wait for price action near key levels before entering. 
He <a href="https://x.com/ali_charts/status/1885282349698449868">emphasized</a> that LINK is currently near the mid-range, making it less favourable for new entries.
<ul>
<li>Upper Boundary: $25.75 – A test could lead to rejection and a pullback toward $24 or lower.</li>
<li>Lower Boundary: $22.00 – A retrace here could provide a long opportunity, but a breakdown might signal further downside.</li>
</ul>
Statistics: IntoTheBlock data shows LINK's large transaction volume declined 24.3% and daily active addresses increased by 8.3%. Transactions greater than $100,000 declined from 449 to 325 in a single day. At current price levels, 81% LINK holders are making profit.
Community News: Chainlink <a href="https://blog.chain.link/chainlink-defi-yield-index/">announced</a> the launch of a new product &#8211; Chainlink DeFi Yield Index – targeted at the decentralized finance market. 
It is a data product that leverages the decentralized oracle network's standard to aggregate lending rates across the decentralized finance ecosystem. 
Chainlink also <a href="https://x.com/chainlink/status/1884648067439165907">launched</a> Data Streams on Scroll, a zero-knowledge-proof-powered scaling solution for Ethereum. 
This will enable developers on Scroll's zkEVM platform with access to Chainlink's low-latency market data.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42846550/ripple-announces-chainlink-integration-to-boost-rlusd-stablecoin">Ripple Announces Chainlink Integration To Boost RLUSD Stablecoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AVAX

$LINK

$XLM

Chainlink Up 23% In A Month: What Is Going On With LINK?

JP Morgan analyst Ken Goldman maintains Kraft Heinz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) with a Neutral and lowers the price target from $36 to $32.

JP Morgan Maintains Neutral on Kraft Heinz, Lowers Price Target to $32

JP Morgan analyst Harlan Sur maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Underweight and lowers the price target from $26 to $23.

INTC

JP Morgan Maintains Underweight on Intel, Lowers Price Target to $23

JP Morgan analyst Jeffrey Zekauskas maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Overweight and lowers the price target from $47 to $40.

JP Morgan Maintains Overweight on Dow, Lowers Price Target to $40

Macro Economic Events

Global

Economics

White House Says Trump Has Not Made Up Mind On Tariff Timeline For EU

Haemonetics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) short percent of float has fallen 5.16% since its last report. The company recently reported that it has 4.96 million shares sold short, which is 15.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 11.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Haemonetics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738349123_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Haemonetics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Haemonetics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Haemonetics's peer group average for short interest as a percentage of float is 6.46%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Haemonetics?

Sherwin-Williams's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) short percent of float has fallen 8.05% since its last report. The company recently reported that it has 5.04 million shares sold short, which is 2.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sherwin-Williams Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738349119_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sherwin-Williams has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Sherwin-Williams's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sherwin-Williams's peer group average for short interest as a percentage of float is 3.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Sherwin-Williams?

Qualcomm's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NYSE">QCOM</a>) short percent of float has risen 7.08% since its last report. The company recently reported that it has 24.01 million shares sold short, which is 2.42% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Qualcomm Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738349113_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Qualcomm has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Qualcomm's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Qualcomm's peer group average for short interest as a percentage of float is 5.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

QCOM

(QCOM) - Analyzing Qualcomm's Short Interest

JP Morgan analyst Sebastiano Petti maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Neutral and lowers the price target from $45 to $39.

CMCSA

JP Morgan Maintains Neutral on Comcast, Lowers Price Target to $39

JP Morgan analyst Tami Zakaria maintains Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) with a Overweight and lowers the price target from $515 to $490.

JP Morgan Maintains Overweight on Caterpillar, Lowers Price Target to $490

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/100517/000010051725000015/ual-20250131.htm" title="https://www.sec.gov/ix?doc=/Archives/edgar/data/100517/000010051725000015/ual-20250131.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/100517/000010051725000015/ual-20250131.htm</a>

Comments

Mangoceuticals

Mangoceuticals (MGRX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga